Skip to main content

Generex Biotechnology Corp. (GNBT)

OTCMKTS: GNBT · Delayed Price · USD
0.2007 -0.0003 (-0.15%)
Sep 24, 2021 3:58 PM EDT - Market closed
Market Cap23.77M
Revenue (ttm)692,762
Net Income (ttm)n/a
Shares Out120.82M
EPS (ttm)-0.37
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume221,289
Open0.1749
Previous Close0.2010
Day's Range0.1714 - 0.2070
52-Week Range0.1650 - 0.5000
Beta-2.91
Analystsn/a
Price Target6.00 (+2,889.5%)
Est. Earnings Daten/a

About GNBT

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, i...

IndustryBiotechnology
Founded1983
CEOJoseph Moscato
Employees15
Stock ExchangeOTCMKTS
Ticker SymbolGNBT
Full Company Profile

News

NuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm

MIRAMAR, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO – www.nugenerexio.com), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or th...

3 months ago - GlobeNewsWire

Generex Biotechnology Subsidiary NuGenHealth Contracts with Westside Medicine & Cardiology, Inc. to Provide Remote Pa...

MIRAMAR, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company wit...

4 months ago - GlobeNewsWire

Generex Posts Recording of May 6 Shareholder Conference Call Highlighting its Ii-Key COVID Complete Vaccine™ and its ...

MIRAMAR, Fla., May 10, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company wit...

4 months ago - GlobeNewsWire

Generex Biotechnology Subsidiary NuGenHealth Contracts with Florida Health Care Associates to Provide Remote Patient ...

MIRAMAR, Fla., May 06, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company wit...

4 months ago - GlobeNewsWire

Generex Provides Clarification on Its Ii-Key COVID-19 Complete Vaccine China Partnership Agreement

MIRAMAR, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company wit...

4 months ago - GlobeNewsWire

Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Thursday May 6, 2021 at...

MIRAMAR, Fla., May 04, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company wit...

4 months ago - GlobeNewsWire

Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Agreement with Nexgen Medical for Distribution of Exc...

MIRAMAR, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) subsidiary Olaregen Therapeutix today announced that the company has executed a Distribut...

4 months ago - GlobeNewsWire

NuGenerex Immuno-Oncology Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission

MIRAMAR, Fla., April 12, 2021 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO – www.nugenerexio.com), a subsidiary of Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT)  (“Generex” o...

5 months ago - GlobeNewsWire

Last Chance for Children is Proud to Announce its Partnership with Generex Biotechnology & NuGenerex Immuno-Oncology ...

NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Last Chance for Children's (LCFC) Mission is to help save children's lives anywhere in the world. Due to the COVID-19 pandemic we are now focusing our effort...

5 months ago - GlobeNewsWire

Generex Biotechnology Announces Shareholder Conference Call Scheduled for Thursday May 6, 2021

MIRAMAR, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB: GNBT) (“Generex or the “Company”), an innovative and integrated healthcare holding company with end-to-end sol...

5 months ago - GlobeNewsWire

Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Complete Vaccine™ Development Program

MIRAMAR, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT)  (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has compl...

7 months ago - GlobeNewsWire

Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Friday February 5, 2021...

The access information for the investor conference call is as follows: Domestic US/Canada - 1-(866) 342-8588Direct Toll / International - 1-(203) 518-9865 Program Title: Generex Biotechnology Conference...

7 months ago - GlobeNewsWire

Generex Biotechnology Announces Investor Conference Call Scheduled for Friday February 5, 2021 at 9:00 AM

MIRAMAR, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday February 5, 2021...

8 months ago - GlobeNewsWire

Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Tradema...

MIRAMAR, Fla., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that its majority owned pub...

8 months ago - GlobeNewsWire

Generex and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribu...

MIRAMAR, Fla., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) and subsidiary NuGenerex Immuno-Oncology to...

10 months ago - GlobeNewsWire

Generex signs Worldwide Licensing Deal with China Partners on the Development of an Ii-Key-H1 Swine Influenza Vaccine

MIRAMAR, Fla., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has...

10 months ago - GlobeNewsWire

Generex Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Plat...

MIRAMAR, Fla., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has...

10 months ago - GlobeNewsWire

Generex Announces the Signing of a Framework Agreement with The China CDC, Beijing Guoxin Haixiang Equity Investment ...

MIRAMAR, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has signed...

10 months ago - GlobeNewsWire

NuGenerex Immuno-Oncology Announces the Launch of a New Corporate Website

MIRAMAR, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation ( www.gen erex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/G...

10 months ago - GlobeNewsWire

Generex Sees Way Forward With Long-Lasting Covid-19 Vaccine

Ii-Key technology is safe, and in a breast cancer trial 10 years out, still effective. GNBT is negotiating contracts covering these areas: Malaysia, New Zealand, Australia, Southeast Asia, Singapore, So...

10 months ago - Seeking Alpha

Generex Subsidiary NuGenerex Immuno-Oncology Announces Appointment of Dr. Tamera Coyne-Beasley to the Scientific Advi...

-Dr. Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM is the Derrol Dawkins, MD Endowed Chair in Adolescent Medicine at Children's of Alabama, Professor of Pediatrics and Internal Medicine, Director of the Un...

10 months ago - GlobeNewsWire

Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of a Review Article on Cancer Vaccines Highlightin...

Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design

11 months ago - GlobeNewsWire

Generex Biotechnology Announces Corporate Update and Investor Conference Call: NuGenerex Immuno-Oncology on Thursday ...

MIRAMAR, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for tomorrow’s investor conference call on Thursday Octo...

11 months ago - GlobeNewsWire

NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the...

MIRAMAR, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/...

11 months ago - GlobeNewsWire

Generex Subsidiary NuGenerex Immuno-Oncology Announces World Class Scientific Advisory Board Appointments for its COV...

MIRAMAR, Fla., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has formed...

11 months ago - GlobeNewsWire